Chongqing Zhifei Biological Products (300122.SZ): The DeGu Aconite Insulin Injection (CA508 Injection) has obtained the Phase III clinical trial summary report.
Chinapeptides (300122.SZ) announced that the company recently received the Phase III clinical trial summary report for the DeGummen Winter Double Insulin Injection (CA508 injection) developed by its subsidiary Chongqing Chen'an Biopharmaceutical Co., Ltd. The effectiveness and safety of the DeGummen Winter Double Insulin Injection (CA508 injection) developed by Chen'an Biopharmaceutical are equivalent to the original drug DeGummen Winter Double Insulin Injection (NovoLog), meeting the design requirements for effectiveness and safety evaluation outlined in the "Guiding Principles for Clinical Trials of Diabetes Therapeutics and Biologics."
Chongqing Zhifei Biological Products (300122.SZ) announced that the company recently received the Phase III clinical trial summary report for the Dezhu Mendong Double Insulin Injection (CA508 injection) developed by its subsidiary Chongqing Chenan Biological Pharmaceutical Co., Ltd. The CA508 injection developed by Chenan Biological is comparable in effectiveness and safety to the original drug Dezhu Mendong Double Insulin Injection (Novo Nordisk), meeting the design requirements for efficacy and safety evaluation in the "Guiding Principles for Clinical Trials of Diabetes Therapeutics and Biologics".
Related Articles
QUNABOX GROUP (00917) spent HK$3.6055 million on December 29 to repurchase 150,000 shares.
HEARTCARE-B (06609) repurchased 56,100 shares at a cost of 299.15 million Hong Kong dollars on December 29th.
Great Wall Motor (02333): Set aside a long-term incentive fund of 80 million yuan for the year 2025.
QUNABOX GROUP (00917) spent HK$3.6055 million on December 29 to repurchase 150,000 shares.
HEARTCARE-B (06609) repurchased 56,100 shares at a cost of 299.15 million Hong Kong dollars on December 29th.
Great Wall Motor (02333): Set aside a long-term incentive fund of 80 million yuan for the year 2025.
